new arga
new arga
  • Home
  • Team
  • Technology
  • Energy Delivery
  • Physicians
  • News
  • Investors
  • Contact
  • More
    • Home
    • Team
    • Technology
    • Energy Delivery
    • Physicians
    • News
    • Investors
    • Contact

  • Home
  • Team
  • Technology
  • Energy Delivery
  • Physicians
  • News
  • Investors
  • Contact

PAF Enrollment Complete in COHERENT-AF FDA IDE Trial

Argá Medtech is pleased to announce the completion of enrollment in the paroxysmal atrial fibrillation (PAF) cohort of COHERENT-AF, its pivotal U.S. Investigational Device Exemption (IDE) study of the Coherent Sine Burst Electroporation (CSE) Ablation Platform. 


The PAF cohort enrolled 150 intention-to-treat subjects across 27 sites in Europe and the United States. Enrollment in the persistent AF cohort is ongoing and expected to complete in the next two months.


Read the full press release here


Copyright © 2024 Argá Medtech SA - All Rights Reserved.

  • Home
  • Team
  • Technology
  • Energy Delivery
  • Physicians
  • News
  • Investors
  • Contact

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Please Note

Arga Medtech will not call, text, or email asking for

sensitive information without prior contact and 

proper channels having been established.